MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$112,181,000
EPS
-$1.11
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue (note 9)
0
0
0
0
Research and development
99,224,000
88,508,000
87,699,000
77,054,000
General and administrative
23,931,000
23,820,000
22,068,000
19,282,000
Total operating expenses
123,155,000
112,328,000
109,767,000
96,336,000
Loss from operations
-123,155,000
-112,328,000
-109,767,000
-96,336,000
Interest income
12,145,000
6,907,000
5,340,000
6,206,000
Unrealized fair value gain on trading securities
-
-
0
-
Foreign exchange loss (gain)
-311,000
548,000
-296,000
-89,000
Total other income
11,834,000
7,455,000
5,044,000
6,117,000
Loss before income taxes
-111,321,000
-104,873,000
-104,723,000
-90,219,000
Income tax recovery
-585,000
-2,571,000
538,000
677,000
Net loss
-110,736,000
-102,302,000
-105,261,000
-90,896,000
Unrealized gain (loss) on available-for-sale securities (note 5)
-1,445,000
-1,546,000
-
364,000
Comprehensive loss
-112,181,000
-103,848,000
-
-90,532,000
Basic EPS
-1.11
-1.17
-1.34
-1.15
Diluted EPS
-1.11
-1.17
-1.34
-1.15
Basic Average Shares
99,609,804
87,345,717
80,126,080
79,247,976
Diluted Average Shares
99,609,804
87,345,717
80,126,080
79,247,976
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$112,181,000
(-33.94%↓ Y/Y)
Net loss
-$110,736,000
(-30.73%↓ Y/Y)
Unrealized gain (loss) on
available-for-sale securities...
-$1,445,000
(-252.27%↓ Y/Y)
Income tax recovery
-$585,000
(6.55%↑ Y/Y)
Interest income
$12,145,000
(68.70%↑ Y/Y)
Loss before income
taxes
-$111,321,000
(-30.46%↓ Y/Y)
Total other income
$11,834,000
(33.01%↑ Y/Y)
Foreign exchange loss
(gain)
-$311,000
(-118.32%↓ Y/Y)
Loss from operations
-$123,155,000
(-30.70%↓ Y/Y)
Total operating
expenses
$123,155,000
(30.70%↑ Y/Y)
Research and development
$99,224,000
(32.33%↑ Y/Y)
General and
administrative
$23,931,000
(24.36%↑ Y/Y)
Buy us a coffee
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)